This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...